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Abstract
Introduction: There exists a small subset of children with autism spectrum disorders (ASD) characterized by
fluctuating behavioral symptoms and cognitive skills following immune insults. Some of these children also exhibit
specific polysaccharide antibody deficiency (SPAD), resulting in frequent infection caused by encapsulated
organisms, and they often require supplemental intravenous immunoglobulin (IVIG) (ASD/SPAD). This study
assessed whether these ASD/SPAD children have distinct immunological findings in comparison with ASD/non-
SPAD or non-ASD/SPAD children.
Case description: We describe 8 ASD/SPAD children with worsening behavioral symptoms/cognitive skills that are
triggered by immune insults. These ASD/SPAD children exhibited delayed type food allergy (5/8), treatment-resistant
seizure disorders (4/8), and chronic gastrointestinal (GI) symptoms (5/8) at high frequencies. Control subjects included
ASD children without SPAD (N = 39), normal controls (N = 37), and non-ASD children with SPAD (N = 12).
Discussion and Evaluation: We assessed their innate and adaptive immune responses, by measuring the
production of pro-inflammatory and counter-regulatory cytokines by peripheral blood mononuclear cells (PBMCs)
in responses to agonists of toll like receptors (TLR), stimuli of innate immunity, and T cell stimulants. Transcription
profiling of PB monocytes was also assessed. ASD/SPAD PBMCs produced less proinflammatory cytokines with
agonists of TLR7/8 (IL-6, IL-23), TLR2/6 (IL-6), TLR4 (IL-12p40), and without stimuli (IL-1ß, IL-6, and TNF-a) than
normal controls. In addition, cytokine production of ASD/SPAD PBMCs in response to T cell mitogens (IFN-g, IL-17,
and IL-12p40) and candida antigen (Ag) (IL-10, IL-12p40) were less than normal controls. ASD/non-SPAD PBMDs
revealed similar results as normal controls, while non-ASD/SPAD PBMCs revealed lower production of IL-6, IL-10
and IL-23 with a TLR4 agonist. Only common features observed between ASD/SPAD and non-ASD/SPAD children is
lower IL-10 production in the absence of stimuli. Transcription profiling of PB monocytes revealed over a 2-fold up
(830 and 1250) and down (653 and 1235) regulation of genes in ASD/SPAD children, as compared to normal (N =
26) and ASD/non-SPAD (N = 29) controls, respectively. Enriched gene expression of TGFBR (p < 0.005), Notch (p <
0.01), and EGFR1 (p < 0.02) pathways was found in the ASD/SPAD monocytes as compared to ASD/non-SPAD
controls.
Conclusions: The Immunological findings in the ASD/SPAD children who exhibit fluctuating behavioral symptoms
and cognitive skills cannot be solely attributed to SPAD. Instead, these findings may be more specific for
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Background
Mounting evidence indicate that ASD is a behaviorally
defined syndrome associated with multiple genetic and
environmental factors, resulting in similar behavioral
symptoms [1-4]. The exceptions are small subsets of
patients with known gene mutations (up to 15-20%) [5].
Consequently, ASD is characterized by varying clinical
phenotypes and a high frequency of co-morbidities.
These co-morbid conditions often have inflammatory
components and inflammation and immune activation
has been implicated in ASD pathogenesis [6,7]. However,
previous studies addressing immune abnormalities in
A S Dc h i l d r e nh a v eb e e ni n c o n clusive, partly due to the
marked heterogeneity of the study subjects.
Previously, we reported a subset of ASD children whose
clinical symptoms are characterized by worsening beha-
vioral symptoms and loss of once acquired cognitive skills
triggered by benign immune insults, typically common
childhood infection [8]. Among this subset of ASD chil-
dren, designated as the ASD-test group in the previous
study, we found a high frequency of immunodeficiency
(mainly SPAD), requiring treatment of intravenous immu-
noglobulin (IVIG) [8]. SPAD is clinically characterized by
impaired antibody production against encapsulated organ-
isms that are common causes of pneumonia, sinusitis, and
ear infection. Therefore, in the previous study, ASD/SPAD
children were excluded from the further analysis, due to
the concern that the presence of SPAD and resultant pre-
s e n c eo fa c t i v ei n f e c t i o nm a ya f f e c tt h er e s u l t so fo u r
immunological assays. Thus, we do not know whether
ASD/SPAD children with fluctuations in behavioral symp-
toms/cognitive skills have the innate immune abnormal-
ities observed in the ASD test group [8] or if they manifest
immune abnormalities more specific for SPAD.
In the Pediatric Allergy/Immunology (A/I) Clinic at our
institution, we follow 8 ASD/SPAD children who have
worsening behavioral symptoms/cognitive skills with
immune insults. In these ASD/SPAD children, even after
improved control of infectious complications with IVIG,
we still observe worsening behavioral symptoms/cognitive
skills that are triggered by immune insults. These children
also seem to have treatment-resistant seizure disorders at
a higher frequency than the ASD/non-SPAD children. In
our observation, there were no differences between ASD/
SPAD children and non-ASD children with SPAD (non-
ASD/SPAD) in the routine immune workups. Infectious
complications observed in these ASD/SPAD children in
our clinic were very similar to those observed in non-
ASD/SPAD children [9]. Innate immune responses are not
routinely studied in conventional immune workups for
SPAD. Since our previous studies have indicated innate
immune abnormalities in the ASD test group children [8],
we hypothesized that innate immune responses affecting
the development of adaptive cellular and humoral immu-
nity are altered in the ASD/SPAD children who reveal
worsening behavioral symptoms and cognitive skills with
immune insults. We also hypothesized that these altered
immune responses are not attributed to SPAD but are
associated with their characteristic neuropsychiatric symp-
toms as described above, perhaps reflecting impaired neu-
roimmune network.
In this study, we tested our hypotheses by further char-
acterizing 8 ASD/SPAD children with fluctuating beha-
vioral symptoms/cognitive skills, by analyzing their
clinical features and immunological findings in compari-
son with three control groups: ASD/non-SPAD children,
normal control children, and non-ASD/SPAD children.
The obtained results support our initial hypothesis, that
peripheral blood mononuclear cells (PBMCs) from ASD/
SPAD children reveal distinct innate and adaptive
immune abnormalities not shared by ASD/non-SPAD or
non-ASD/SPAD children.
Case description
ASD/SPAD children
Eight ASD/SPAD children characterized by fluctuating
(worsening) behavioral/cognitive skills following immune
insults including viral infection and adverse reactions to
medications were presented in this study. The demo-
graphics, diagnosis, co-morbidities, and clinical laboratory
findings of these ASD/SPAD children are summarized in
Tables 1 and 2. These ASD/SPAD children had at least 3
occurrences of worsening behavioral symptoms and/or
loss of once acquired cognitive skills documented follow-
ing immune insults such as viral syndrome; viral syndrome
(upper respiratory infection and acute gastroenteritis) was
clinically diagnosed with negative streptococcal antigen in
throat swab and in some cases, supported by positive viral
antigen and/or DNA in nasal secretions by PCR. Occur-
rences of worsening behavioral symptoms were indepen-
dently documented by caretakers, teachers, and therapists.
SPAD was diagnosed with detectable antibody (Ab) titers
(> 1.0 μg/ml) to less than 3 of 14 serotypes of Streptococ-
cus pneumonia tested in response to Pneumovax
® [10], a
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SPAD children evaluated in this study are currently on
IVIG (0.6-1 g/kg/dose every 3 weeks), since their infection
complications were not controlled effectively with prophy-
lactic antibiosis. Assay samples were obtained when their
infectious complications were well under control after
implementation of IVIG treatment. The ages of ASD/
SPAD children at the time of sample obtainment were
12.3 yr (median) with range of 8.3-17.5 yr. The length of
IVIG treatment varied from 1 to 6 yrs, at the time blood
Table 1 Demographics and clinical features of the ASD/SPAD children
Case Age
1
(yr)
Race Sex Immuno-deficiency
Diagnosis
Autism
Diagnosis
Infection Other co-morbidities and medications
3
#1
4 13 W M SPAD
5 Regressive autism CRS,
ROM
Chronic enterocolitis, asthma
fluoxetine, montelukast,
#2
4 11 W M SPAD Regressive autism CRS,
ROM
Seizure disorder
7, Chronic enterocolitis
levetiracetam, montelukast, loratadine,
#3
4 8 W M SPAD Regressive autism CRS Chronic enterocolitis, allergic rhiniconjunctivitis
fluoxetine, montelukast, cetirizine, mometasone nasal
inhaler
#4
4 9 W M SPAD PDD-NOS
(regressive)
ROM Seizure disorder
valproic acid, L-carnitine, CQ10
#5
2,4 14 W F SPAD Regressive autism CRS,
ROM,
Seizure disorder, Chronic enterocolitis, asthma
montelukast, desloratadine, minocycline (for acne),
lorazepam
#6 16 W M SPAD Regressive autism CRS Asthma, chronic enterocolitis
Steroid oral inhaler, nasal inhaler, guanfacine
#7 7 W F SPAD PDD-NOS
(regressive)
CRS,
ROM
Seizure disorder
montelukast, nasal inhaler, levetiracetam, azithromycin
(prophylaxis)
#8 6 mixed M SPAD
6 Regressive autism COM guanfacine, risperidone, benzatropine
1 Ages at the time of SPAD diagnosis. It should be noted that Case #1 and Case #2 were followed up in the clinic for 2-3 yrs prior to SPAD diagnosis but their
initial laboratory values were not consistent with SPAD diagnosis. Their clinical features progressed over 2-3 yrs to fulfill the diagnosis of SPAD.
2 This patient developed anti-phospholipid syndrome 5 yrs after being treated with IVIG.
3 Co-morbidities present at the time of presentation and medications at the time of sample obtainment.
4 Positive history of food protein induced enterocolitis syndrome (FPIES)
5 Abbreviations used: COM (chronic otitis media), CRS (chronic rhinosinusitis), PDD-NOS (pervasive developmental disorder, not otherwise specified), ROM
(recurrent otitis media), SPAD (specific polysaccharide deficiency), and W (Caucasians)
6 This patient also revealed low IgG levels but did not fall into the diagnostic criteria for common variable immunodeficiency; immunoglobulin levels of 2
isotypes are lower than two standard deviations of mean values of age-appropriate controls.
7 In Case #2 and Case #7, a main trigger of seizure activities has been respiratory infection. In Case#7, onset of seizure clusters were almost always triggered by
respiratory infection prior to IVIG treatment. After implementation of IVIG treatment, no clinical seizures have been observed in case #2. In case #7, seizure
activity appears to be not associated with infection any more after starting IVIG treatment and prophylaxis doses of azithromycin (3 times per week).
Table 2 Summary of conventional immune workup results in ASD/SPAD children
Case# IgG
1 (mg/dL) IgA (mg/dL) IgM (mg/dL) Pneumococcal
antibody titers
2
N > 11/14
Isotype-switched memory B cells
(cells/μl)
3
N = 39.9 (27.1-97.6)
4
Total memory B cells
(cells/μl)
N = 77.5 (55.1-198)
4
#1 545 23 96 0/14 7.6 19.6
#2 844 116 190 0/14 8.3 13.2
#3 680 35 23 0/14 6.1 15.1
#4 767 34 59 1/14 5.4 25.0
#5 578 121 136 0/14 2.7 2.9
#6 783 40 107 0/14 21.9 31.0
#7 700 38 29 2/14 8.0 40.8
#8 442 44 66 2/14 1.9 19.0
1 Normal ranges of Ig levels (mg/dl) are for children of 6-8 yr (IgG; 572-1374, IgM; 30-208, IgA; 34-305) for children of 9-11 yr (IgG; 586-1496, IgM; 48-228, IgA; 45-
305) and for children of 12-16 yr (IgG 759-1549, IgM; 35-239, IgA; 58-358).
2 Numbers of serotypes revealed > 1.0 μg/ml Ab levels among Streptococcus pneumonia 14 serotypes tested. Children > 5 yr is expected to reveal protective
levels of Ab titers > 75% of 14 serotype.
3 Isotype switched memory B cell numbers identified as IgD
-, CD27
+, CD19
+ cells and total memory B cell numbers (CD27
+, CD19
+ cells) were expressed as cell
numbers/μl of peripheral blood.
4 Reference values of these parameters obtained from 27 normal controls (Age; 2-17 yr) in our laboratory are shown as a median (range).
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low 2 ASD/SPAD children without fluctuation in beha-
vioral symptoms/cognitive skills. They responded very
well to IVIG treatment for controlling infections but we
did not observe any changes in their autistic features.
These children were not included in the current study.
We refer ASD/SPAD children as these 8 ASD/SPAD chil-
dren with worsening behavioral symptoms and cognitive
skills with immune insults in this study.
In both ASD/SPAD and ASD/non-SPAD children, aut-
ism diagnosis was from established autism diagnostic cen-
ters, including the center at our institution. Standard
diagnostic measures, including ADOS (Autism Diagnostic
Observational Schedules), and ADI-R (Autism Diagnostic
Interview-Revised) were used. Diagnosis of allergic disor-
ders and asthma were based on diagnostic criteria
described elsewhere [11-13].
Control subjects
1. ASD/non-SPAD children: These children were recruited
in the Subspecialty Clinic at UMDNJ-NJMS where subspe-
cialties include allergy/immunology, cardiology, develop-
mental pediatrics, endocrinology, gastroenterology,
genetics, general pediatrics, nephrology, and pulmonology.
A total of 39 ASD/non-SPAD children were recruited to
the study: 4 females and 35 males, median age: 8.1 yr,
range; 5-17 yr, 7 African Americans (AA), 3 Asians, 27
Caucasians (W), and 2 mixed races. These ASD/non-
SPAD children were diagnosed with autism (N = 25) or
PDD-NOS (N = 14). Twenty out of 39 children reported
to have developmental regression at the time of initial
diagnosis of ASD. Allergic rhinoconjunctivitis (AR+AC)
was diagnosed in 5/39 (12.8%) ASD/non-SPAD children.
None of the control ASD/non-SPAD children were docu-
mented to have recurrent infection and/or fluctuating
behavioral symptoms/cognitive skills following immune
insults. In addition, none of these ASD/non-SPAD con-
trols were diagnosed with seizure disorders.
2. Normal controls: Normal control children (N = 37, 8
females and 29 males, median age; 10.2 yr, range: 5-17 yr,
4AA, 1 Asian, 31 W, and 1 mixed race) were recruited in
the Pediatric Subspecialty Clinic. In most cases, blood
samples were obtained when they were medically indi-
cated to have venipuncture for general health screening.
3. Non-ASD/SPAD children: A total of 12 non-ASD/
SPAD children were recruited in the pediatric Allergy/
Immunology Clinic; median age; 13.0 yr, range; 6-17 yr, 6
females and 6 males, 4 AA and 8 W. SPAD diagnosis was
made as described in ASD/SPAD children in the previous
section [10]. All of them have been treated with IVIG (0.6-
1 g/kg/dose every 3 weeks) and were on IVIG treatment at
the time of sample obtainment. The length of IVIG treat-
ment was 1 to 7 yrs for these children at the time of this
study. Two out of 12 patients were diagnosed with seizure
disorders; in 1 patient, the seizure disorder was attributed
to sequel of intracranial abscess developed from chronic
rhinosinusitis and in 1 patient, the etiology of seizure dis-
order is unknown.
Sample obtainment The study subjects were recruited
following study protocols approved by the Institutional
Review Board, University of Medicine and Dentistry of
New Jersey-New Jersey Medical School (UMDNJ-NJMS).
Blood samples were collected after obtainment of signed
parental consent forms. Signed assent forms were also
obtained, if applicable, in children older than 7 years of
age.
At the time of sample obtainment, all the subjects were
examined to ensure absence of active infection. Assays for
adaptive and innate immunity for SPAD children, with or
without ASD, were conducted after their conditions were
stabilized by IVIG and became free from active infection.
In most cases, sample obtainment coincided with medi-
cally indicated blood work.
Clinical and laboratory findings in ASD/SPAD chil-
dren by conventional immune workup Most of the
ASD/SPAD children suffered from chronic rhinosinusitis
(CRS) and recurrent otitis media (ROM) requiring fre-
quent antibiosis prior to IVIG treatment. Four out of 8
(50%) ASD/SPAD children had history of multiple place-
ments of pressure equalizing (PE) tubes bilaterally (Table
1). ASD/SPAD children also revealed a high frequency of
treatment-resistant seizure disorders (4/8, 50%), while
none of the normal and ASD/non-SPAD control children
had a history of seizure disorders. However, 25/40 (62.5%)
ASD/non-SPAD children had a history of food protein
induced enterocolitis syndrome (FPIES), although at the
time of blood sampling, none of them had active GI symp-
toms. ASD/SPAD children also had history of FPIES at a
similar rate (5/8, 62.5%) and these ASD/SPAD children
with history of FPIES suffered from chronic enterocolitis,
even after IVIG treatment, requiring dietary intervention
measures (avoidance of offending food). In these ASD/
SPAD children with GI symptoms, extensive workups
ruled out chronic microbial infection, celiac disease,
inflammatory bowel diseases, or other well established GI
diseases by endoscopic and histological examinations.
None of the ASD/SPAD subjects revealed positive allergy
workups; they all had normal IgE levels, negative reactivity
to prick skin testing (PST), or negative for food allergen
specific IgE. All the ASD/SPAD children were diagnosed
with regressive type ASD (Table 1).
As shown in Table 2, immune workups, at initial diag-
nosis of SPAD, revealed low to low normal serum levels of
IgG, IgA, and IgM as compared to age-appropriate con-
trols in 4/8, 6/8, and 6/8 ASD/SPAD children. Numbers of
isotype-switched memory B cell were lower than 10/μli n
7/8 ASD/SPAD children [14]. Infection was better con-
trolled after initiation of IVIG treatment in all the ASD/
SPAD children, which was also associated with a reduction
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by infection. After being treated with several doses of
IVIG, the parents of one patient reported the return of
cognitive skills that were present prior to major regression.
However, 7/8 ASD/SPAD children did not reveal signifi-
cant improvement in autism behavioral symptoms or cog-
nitive activity, per parental reports assessed by the clinical
global impression scale (CGI) [15]. In the ASD/SPAD
patients with seizure disorders, frequency of seizures was
reduced after starting IVIG treatment, which is likely
attributed to better control of infection, since the major
trigger of seizure activity is infection for these subjects.
Further Evaluation of immune functions
1. PBMC Cultures PBMCs were isolated by Ficoll-Hypa-
que density gradient centrifugation. Innate immune
responses were assessed by incubating PBMCs (10
6 cells/
ml) overnight with TLR4 agonist (LPS; 0.1 μg/ml,
GIBCO-BRL, Gaithersburg, MD), TLR2/6 agonist (zymo-
san; 50 μg / m l ,S i g m a - A l d r i c h ,S t .L u i s ,M o ) ,T L R 3a g o -
n i s t( P o l yI : C ,P o l yI : C ,0 . 1μg/ml, Sigma-Aldrich), and
TLR7/8 agonist (CL097, water-soluble derivative of imi-
dazoquinoline, 20 μM, InvivoGen, San Diego, CA) in
RPMI 1640 with additives as previously described [8].
Overnight incubation was adequate to induce the optimal
responses in this setting. Levels of proinflammatory
[tumor necrosis factor-a (TNF-a), IL-1b, IL-6, IL-12p40,
and IL-23] and counter-regulatory [IL-10, transforming
growth factor-ß (TGF-ß) and soluble TNF receptor II
(sTNFRII)] cytokines in culture supernatant were then
measured by an enzyme-linked immunosorbent assay
(ELISA).
Cellular reactivity to T cell stimulants was assessed by
incubating PBMCs (10
6 cells/ml) with T cell mitogens
[Con A (2 μg/ml) and PHA (5 μg/ml)], recall Ag [candida
Ag (5 μg/ml), Greer, Lenoir, NC], and IFN-g inducing
cytokines [IL-12p70 (0.2 ng/ml, BD Biosciences, San
D i e g o ,C A ) ,I L - 1 8( 1n g / m l ,B DB i o s c i e n c e s )f o r4d a y s
and measuring levels of IFN-g,T N F - a, IL-5, IL-10,
IL-12p40, and IL-17 in the culture supernatant [8]. Initial
titration studies showed that a four-day incubation period
resulted in optimal production of these cytokines, in this
setting.
Cytokine levels were measured by ELISA, using
OptEIA™ Reagent Sets (BD Biosciences) for IFN-g, IL-1ß,
IL-5, IL-6, IL-10, IL-12p40, and TNF-a, and ELISA
reagent set (R & D, Minneapolis, MN) for sTNFRII, IL-17
(IL-17A), and TGF-ß. IL-23 ELISA kit was purchased
from eBiosciences, San Diego, CA. Intra- and inter-varia-
tions of cytokine levels were less than 5%.
2. Flow cytometry Memory B cells (IgD
-, CD27
+, CD19
+
B cells) were detected by staining with anti-CD45-FITC,
anti-CD19-APC-Cy7, CD27-APC (all from BD bios-
ciences, San Jose CA) and IgD-PE (DAKO, Carpinteria
CA) monoclonal antibodies [14]. For intracellular
cytokine staining in CD4
+ T cells, the following fluoro-
chrome-conjugated monoclonal antibodies were used:
CD4-PerCp, IFN-g-PE-Cy7, IL-17-PE, IL-4-FITC, IL-10-
Pacific Blue (all from eBiosicences), and TGF-ß-APC
(R & D, Minneapolis, MN). PBMCs were incubated over-
night (16 h) at 37°C with medium alone, Staphylococcal
enterotoxin B (5 μg/mL, Sigma-Aldrich), or candida Ag
(5 μg/ml, Greer) in the presence of Brefeldin A (BFA; 5
μg/ml, Sigma-Aldrich), anti-CD28 (1 μg/ml, eBios-
ciences), and anti-CD49 (1 μg/ml, eBiosciences) in the
same culture medium used for the cytokine production
assay. Then PBMCs were permeabilized (permeabilization
buffer, BD Biosciences) and stained with the above
described antibodies [16]. All flow cytometry was con-
ducted using FACS Caliber or FACSVantage SE TM (BD
Biosciences) and the data were analyzed with the Cell-
Quest software (BD Biosciences) and FlowJo (TreeStar,
Ashland, OR).
3. Transcription profiling Peripheral blood (PB) mono-
cytes were purified using an immuno-affinity column fol-
lowing the manufacturer’s instructions (MACS monocytes
isolation kit, Miltenyi Biotec, Auburn, CA). Total RNA
were extracted by the RNA easy kit (Quiagen, Valencia,
CA). RNA labeling and hybridizations on Agilent Human
4 × 44K arrays (Agilent, Lexington, MA) were done using
the Agilent One-Color Microarray-Based Gene Expression
Analysis Ver 5.5 protocol (Agilent). All slides were
scanned by an Agilent Scanner and normalized numerical
data were obtained by Agilent Feature extraction software
9.5.
4. Statistical analysis For comparison of test values with
control values, a Wilcoxon rank sum test was used. For
comparison of values of multiple groups, a Kruskall-
Wallis test was used. A Chi square (c
2) test was used to
examine the difference in frequency and correlation was
tested using a linear regression analysis. These tests were
performed using R.2.10.1 (R-Development Core Team
2009). A p value of < 0.05 was considered to be statisti-
cally significant. For the analysis of microarrays experi-
ments, Gene Spring GX v11 software (Agilent) was used.
After filtering for “present” calls in at least 20% of sam-
ples, fold change analysis were performed for group for
comparisons on 26992 probes. Genes with at least a two-
fold change, as compared to controls, are determined to
be either up-regulated or down-regulated. Using a speci-
fic module of GeneSpring software (Agilent), pathways
enrichment analysis was performed on those up- or
down-regulated genes to see if there is a statistically sig-
nificant enrichment (p < 0.05) for specific BioPax
pathways.
5. Cytokine production results As stated above, the med-
ian ages of the study subjects at the time of sample
obtainment are 12.3 yr for ASD/SPAD children, 8.1 yr
for ASD/non-SPAD children, 10.2 yr for normal controls,
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non-SPAD children were lower than ASD/SPAD and
non-ASD/SPAD children (p < 0.05). It should be noted
that innate immune responses, as opposed to adaptive
immune responses, are not expected to change with age.
This is mainly because innate immunity is regulated by
germ-line coded genes and has little post-natal modifica-
tions, such as gene rearrangement.
Responses to TLR agonists
ASD/SPAD PBMCs produced different patterns of cyto-
kine production. Namely, ASD/SPAD PBMCs produced
lower amounts of IL-6 (without a stimulus and with
TLR2/6 agonists), IL-1ß (without a stimulus), and IL-23
(with TLR 7/8 agonist) as compared to all the control
groups (Figure 1 A, B, C). In, addition, ASD/SPAD
PBMCs produced less IL-12p40 than normal and non-
ASD/SPAD control cells in response to a TLR4 agonist
(Figure 1-A). These cells also produced lower amounts
of IL-6 (with the TLR 7/8 agonist) and TNF-a/IL-10 (in
the absence of stimulus) than normal controls (Figure 1-
B). PBMCs from ASD/non-SPAD children revealed
similar patterns of cytokine production as compared to
normal controls (Figure 1). In contrast, non-ASD/SPAD
PBMCs revealed altered patterns of cytokine production
which did not resemble those observed in ASD/SPAD
children. That is, non-ASD/SPAD PBMC revealed lower
IL-10 production than ASD/SPAD and normal control
cells (Figure 1-A) and lower IL-6/IL-23 production than
normal controls (Figure 1-C, D) in response to a TLR4
agonist. The only common feature observed between
the ASD/SPAD and non-ASD/SPAD groups was pro-
duction of lower levels of IL-10 in the absence of a sti-
mulus, than normal controls (Figure 1-C). These results
indicate that the altered responses to TLR agonists
observed in the ASD/SPAD group are unlikely to be
associated with SPAD.
Responses to the recall antigen and T cell mitogens
ASD/SPAD PBMCs also revealed altered patterns of T
cell cytokine production as compared to control groups.
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Figure 1 Cytokine production by PBMCs from ASD/SPAD, normal control, ASD/non-SPAD and non-ASD/SPAD children when
stimulated by TLR agonists. IL-12p40/IL-10 production with TLR4 agonist (LPS) (Panel A), IL-6 production with TLR2/6 and 7/8 agonists or
without a stimulus (Panel B), spontaneous production of TNF-a, IL-1ß, and IL-10 as well as IL-23 production with TLR4 and 7/8 agonists (Panel C),
and IL-6 production with TLR4 agonist (Panel D) was shown. PBMCs (10
6 cells/ml) were incubated with TLR agonists as indicated overnight and
cytokine levels in the culture supernatant were measured by ELISA. In Figs 1-2, the results of cytokine production with stimuli shown were those
corrected by subtracting the levels of cytokines produced without a stimulus. *; lower than all the study groups (p < 0.05).
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Page 6 of 12and IL-10 than all the study groups in response to a
recall Ag (candida Ag) (Figure 2-B). In addition, ASD/
SPAD PBMCs produced less IFN-g and IL-17A with
PHA, and less IL-12 with Con A as compared to normal
controls (Figure 2-A). Moreover, amounts of IL-17A
produced by ASD/SPAD PBMCs with PHA was also
lower than that of non-ASD/SPAD cells (Figure 2-A). IL-
12 production with Con A by ASD/SPAD cells was also
lower than that of ASD/non-SPAD controls (Figure 2-A).
Production of T cell cytokines by ASD/non-SPAD and
non-ASD/SPAD cells did not differ from normal controls
in response to T cell mitogens or candida Ag (Figure 2-A
& 2B). TGF-ß is produced in high amounts sponta-
neously and does not increase much in response to T cell
stimuli. However, interestingly, we observed a higher
increase in TGF-ß production in response to candida Ag
in the ASD/SPAD group than normal and non-ASD/
SPAD groups. Again, these results indicate that altered
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Figure 2 Cytokine production by PBMCs from ASD/SPAD, normal control, ASD/non-SPAD and non-ASD/SPAD children when
stimulated by mitogens (PHA or Con A) (Panel A) or candida Ag (Panels B and C). PBMCs (10
6 cells/ml) were incubated with T cell
stimulants (PHA, Con A, and candida Ag) for 4 days and cytokine levels in the culture supernatant were measured by ELISA. Secondary to high
production of TGF-ß without a stimulus, the production of TGF-ß is expressed as stimulation index (ratio of TGF-ß produced with candida Ag/
background TGF-ß produced without a stimulus). *; lower than all the study groups (p < 0.05).
Jyonouchi et al. Journal of Neuroinflammation 2012, 9:4
http://www.jneuroinflammation.com/content/9/1/4
Page 7 of 12patterns of T cell cytokine production by the ASD/SPAD
PBMCs is unlikely to be attributed to SPAD.
When intracellular expression of Th1 (IFN-g), Th2
(IL-4), Th17 (IL-17A), and regulatory cytokines (IL-10
and TGF-ß) were examined in 6/8 ASD/SPAD children,
we observed lower intracellular expression of TGF-b in
CD4
+ cells, as compared to age-appropriate controls
(ASD/non-SPAD children N = 18, normal controls N =
26, and non-ASD/SPAD children N = 9) (Figure 3).
6. Transcription profiling of PB monocytes Since most
notable changes were found in TLR responses in ASD/
SPAD children and these changes were not observed in
non-ASD/SPAD controls, we conducted transcription pro-
filing of PB monocytes, a major cell population of PB
innate immune cells responding to TLR agonists. Tran-
scription profiling was conducted in 7 ASD/SPAD, 28
ASD/non-SPAD, and 26 normal control children. We
were unsuccessful in 2 our attempts to purify total RNA
from PB monocytes of 1 ASD/SPAD child; this may be
associated with the high dose of valproic acid that he was
on in order to control his seizure activities. Our results
revealed that significant numbers of genes were either up
or down-regulated (> 2 fold) in ASD/SPAD monocytes as
compared to controls, as summarized in Table 3. Up-regu-
lated genes as compared to control groups included che-
mokines (CCL2 and CCL7). Pathway analysis of gene
expression profiles revealed that ASD/SPAD children had
enriched expression of genes involved in TGFBR (TGF-ß
receptor), EGFR (epidermal growth factor receptor), and
NOTCH pathways as compared to ASD/non-SPAD con-
trols (Table 3).
Discussion and Evaluation
Clinical features of infection found in ASD/SPAD children
are similar to those found in non-ASD/SPAD children and
all of the ASD/SPAD children suffered from frequent sino-
pulmonary infection (Table 2) [17]. As expected, infections
were better controlled, once IVIG treatment was in place
[18,19]. However, the ASD/SPAD children revealed a
higher frequency of seizure disorders as compared to non-
ASD/SPAD children (4/8, 50% vs. 2/12 16.7%). In 2/4
ASD/SPAD children with seizure disorders, seizure activity
was often associated with infection and is better controlled
after implementation of IVIG treatment (Table 1). No sub-
jects in the normal control and ASD/non-SPAD groups
suffered from seizure disorders. As noted previously, these
ASD/SPAD subjects are those with markedly worsening
behavioral symptoms/cognitive skills following each
immune insult [8]. These results raise the question of
whether the immune abnormalities that are associated
with SPAD, contribute to the clinical features observed in
the ASD/SPAD children. Alternatively, it may be possible
that SPAD is a part of the clinical features that develop
with age in the ASD/SPAD children and are associated
with immune abnormalities that affect Ab production and
possibly the neuroimmune network. Interestingly, in 3/4
ASD/SPAD subjects with seizure disorders, SPAD was
diagnosed several years later after the diagnosis of seizure
disorders.
Routine immune workups of ASD/SPAD children did
not reveal major defects of T or B cells, except for those
indicating impaired antibody production typically found in
SPAD patients (Table 2). Infectious complications in the
ASD/SPAD children were very similar to those observed
in non-ASD/SAPD children [9]. Therefore, pathogen-spe-
cific mechanisms are unlikely to explain neuropsychiatric
symptoms of fluctuating behavioral symptoms/cognitive
skills in the ASD/SPAD children examined in this study.
When innate immune responses were assessed, by mea-
suring responses to a panel of TLR agonists, we observed
significant differences in the ASD/SPAD children, as com-
pared to control groups. That is, PBMCs from the ASD/
SPAD children tended to produce less pro-inflammatory
cytokines (TNF-a, IL-1ß, IL-6, IL-12, and IL-23). Changes
were most evident in the production of IL-6. As for pro-
duction of counter-regulatory cytokines, PBMCs from
ASD/SPAD children revealed less spontaneous IL-10 pro-
duction than normal controls. Responses to TLR agonists
in the non-ASD/SPAD children differed significantly from
those observed in the ASD/SPAD children as detailed in
the results section and Figure 1. Only common feature
found in both the ASD/SPAD and non-ASD/SPAD chil-
dren was lower spontaneous production of IL-10 than
normal controls (Figure 1-C).
Since ASD/SPAD children are on multiple medica-
tions for asthma, chronic rhinitis, and infection
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Page 8 of 12prophylaxis which included montelukast, steroid oral/
nasal inhalers, anti-histamines, and azithromycin pro-
phylaxis, these finding could be attributed to medica-
tions that they were on. However, non-ASD/SPAD
children were also on multiple medications similar to
those taken by ASD/SPAD children. Therefore it is unli-
kely that these medications are affecting the assay
results. Some ASD/SPAD children were also on anti-sei-
zure medications including levetiracetam (N = 2), val-
p r o i ca c i d( N=1 ) ,a n dl o r a z e p a m( N=1 ) .H o w e v e r ,i t
is hard to assess if these medications can affect the
assay results given low frequency of intake of these
medications among the ASD/SPAD children. Two ASD/
non-SPAD children with seizure disorders were also on
levetiracetam and valproic acid.
IL-6 is important for B cell maturation and Ab produc-
tion [16]. Our finding of impaired IL-6 production in
ASD/SPAD children might be associated with develop-
ment of SPAD in the ASD/SPAD children. Decreased pro-
duction of IL-10 may also indicate a possibility of
prolonged inflammation in ASD/SPAD children. Proin-
flammatory cytokines especially TNF-a,I L - 1 ß ,a n dI L - 6
exert important roles in mediating acute stress responses
and dysregulated production of these cytokines were
implicated with chronic CNS inflammation [20,21], as well
as, schizophrenia [22]. Thus, lower production of these
key cytokines may indicate an impairment of stress
responses or the neuro-immune network in the ASD/
SPAD children with fluctuating behavioral symptoms/cog-
nitive skills.
Cytokines produced by innate immune responses
greatly affect differentiation of T-helper (Th) cell subsets.
IL-1ß, IL-6, and TGF-ß, when combined together, pro-
mote differentiation of Th17 cells, which in turn promote
neutrophilic inflammation and anti-fungal/bacterial
defense [23-25]. IL-23 sustains Th17 cells [23-25]. IL-12
promotes differentiation of Th1 cells [26]. Given
decreased IL-12, IL-6, and IL-1ß production in the ASD/
SPAD children, the question is raised as to whether pro-
duction of T cell cytokines specific for Th cell subsets is
altered in ASD/SPAD children. When we tested T cell
cytokine production, our results revealed lower produc-
tion of IFN-g,T h 1c y t o k i n e ,a n dI L - 1 7 A ,T h 1 7c y t o k i n e ,
in response to PHA in the ASD/SPAD children (Figure
2-A). These results indicate a possible impairment of
Th1 and perhaps Th17 responses in the ASD/SPAD chil-
dren, making them more vulnerable to certain microbial
infection. However, frequency of Th1 and Th17 subsets
identified by intracellular cytokine expression were not
altered in ASD/SPAD children. The non-ASD/SPAD
children did not reveal such changes. Further studies
regarding Th1/Th17 cell development will be required in
the ASD/SPAD children with fluctuating behavioral
symptoms and cognitive skills.
When we tested adaptive immune responses to recall
Ags, we observed significantly less production of IL-10
and IL-12p40 with candida Ag, but higher increase of
TGF-ß production in the ASD/SPAD children, than con-
trol groups. IFN-g or IL-17A production with candida Ag
did not differ among the study groups. Interestingly, 5 of
8 ASD/SPAD children had chronic GI inflammation
often complicated by dysbiosis and/or candida enteritis
with evidence of positive reactivity to candida antigen
when assessed by production of IFN-g and IL-17A pro-
duction at the time of flare up. These children frequently
required treatments with oral anti-fungal medications.
Both IL-10 and IL-12p40 can function as regulatory fac-
tors to control inflammatory responses. Thus a decreased
production of these cytokines with candida Ag may lead
to persistent and excessive immune responses against
candida Ag in the ASD/SPAD children.
Intracellular expression of TGF-b was lower in the
ASD/SPAD children than controls (Figure 7) when sti-
mulated with SEB or candida Ag. These findings indicate
decreased frequency of TGF-b
+ inducible regulatory T
(Treg) cells in the ASD/SPAD children, despite higher
increase in TGF-ß production by ASD/SPAD PBMCs
than controls. TGF-ß is produced by many lineage cells
and the source of TGF-ß in the cultures of ASD/SPAD
PBMCs may not be Treg cells, but other lineage cells.
Such changes were not observed in non-ASD/SPAD chil-
dren. In summary, studies of T cell functions indicate
dysregulated T cell functions in the ASD/SPAD children,
but not in the non-ASD/SPAD children. These findings
may be associated with altered innate immune responses
in the ASD/SPAD children.
Table 3 Summary of transcription profiling results in ASD/SPAD children
Numbers of genes
1 Vs. normal controls Vs. ASD/non-SPAD controls Overlapping in 2 control groups
Up-regulated 830 1258 316
Down-regulated 653 1235 356
Pathway analysis Vs. normal controls Vs. ASD/non-SPAD controls
TGFBR Not significant P < 0.01
EGFR Not significant P < 0.02
NOTCH Not significant P < 0.005
1 The number of genes > 2 fold up- or down-regulated in the ASD/SPAD children as compared to normal controls and ASD/non-SPAD children.
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and undergo spontaneous apoptosis on a daily basis
[27]. In response to various differentiation factors,
monocytes escape their apoptotic fate by differentiating
into macrophages [27,28], which usually happens during
inflammatory responses. PB monocytes are heteroge-
neous consisting of M1 monocytes (CD14++, CD16-
cells) and M2 monocytes (CD14+, CD16+ cells) [27,29].
The majority of PB monocytes is M1 monocytes and
activated M1 monocytes are recruited to the site of
inflammation via chemokines (CCL2 and CCL7) [27,29].
To further extend our investigations, we conducted
transcription profiling of PB monocytes in ASD/SPAD
children in comparison with ASD/non-SPAD and nor-
mal controls. Over 300 genes are either up- or down-
regulated in the ASD/SPAD children, in comparison
with both ASD/non-SPAD and normal control groups
(Table 3). Interestingly, gene expression of CCL2 and
CCL7 was up-regulated in PB monocytes from the
ASD/SPAD children. Recruitment of M1 monocytes has
been implicated with chronic inflammatory conditions,
including those in the CNS [27,30]. Thus, up-regulated
expression of CCL2 and CCL7 may indicate a constant
activation signal occurring in PB monocytes in the
ASD/SPAD children.
The results of transcription profiling of PB monocytes
also revealed enriched expression of genes in TGFBR
(TGF-b receptor), NOTCH, and EGFR (epidermal
growth factor receptor) signaling pathways in ASD/
S P A Dc h i l d r e n ,a sc o m p a r e dt oA S D / n o n - S P A Dc o n -
trols. Pathogen associated molecular patterns (PAMPs)
often up-regulate NOTCH ligands and NOTCH signal-
ing in macrophage/monocyte lineage cells [31], which
can, in turn, affect production of cytokines regulating
Th cell subsets [32]. NOTCH signaling is also known to
affect the activation status of microglial cells and neural
progenitor cells [33-35]. NOTCH and EGFR pathways
are closely inter-related and involved in regulation of
cell differentiation and proliferation [36,37]. TGFBR
pathway activation is implicated with cell proliferation
and wound healing along with its anti-inflammatory
properties of TGF-ß [38]. In addition, TGF-ß pathways
closely interact with NOTCH and EGFR signaling path-
ways [31]. Thus the findings from the transcription pro-
filing of PB monocytes also support our assumption that
ASD/SPAD monocytes are chronically activated which
may be associated with the fluctuating neuropsychiatric
symptoms observed in the ASD/SPAD children. Further
analysis of a larger number of these children in compar-
ison with appropriate controls will be necessary for
further elucidate whether PB monocytes play a role in
the medical conditions of ASD/SPAD children. In addi-
tion, follow-up of these parameters in the ASD/SPAD
children longitudinally will be informative to further
address their immune abnormalities in association with
their above-described clinical features.
Use of IVIG for treatment of autism or its ‘presumed’
autoimmune co-morbid conditions, such as pediatric
autoimmune neuropsychiatric disorders associated with
streptococci (PANDAS), has been controversial, and
clinical trials yielded conflicting results [39-41]. The
controversy surrounding the effects of IVIG on ASD
children is partly attributed to marked heterogeneity of
ASD subjects and relatively small numbers of study sub-
jects. In our cohorts, beneficial effects of IVIG on cogni-
tive skills/behavioral symptoms were observed in only
one of 8 ASD/SPAD subjects, indicating the complexity
of ASD pathogenesis and the need for careful evaluation
of the use of IVIG in ASD children, other than for anti-
body deficiency syndrome.
The limitation of this study is the lack of transcription
profiling data in PB monocytes from the non-ASD/
SPAD children, due to both limited resources and
restrictions associated with the study protocol. However,
to our knowledge, we have not found any literature
describing similar changes in transcript profiles of PB
monocytes in non-ASD/SPAD children. At least two
ASD/SPAD children without fluctuation of behavioral
symptoms/cognitive skills are followed in our clinic. In
these children, we have not observed the immune
abnormalities found in ASD/SPAD children described in
this case series (unpublished observation). These results
again indicate that the immune abnormalities observed
in ASD/SPAD children with fluctuating behavioral
symptoms/cognitive skills are not solely attributed to
SPAD.
Conclusions
In summary, our results revealed distinct clinical and
immunological findings in ASD/SPAD children who
reveal worsening behavioral symptoms/cognitive skills
with immune insults. These immune abnormalities are
not shared by either ASD/non-SPAD or non-ASD/
SPAD children. Thus these abnormalities are likely to
be more specific for this subset of ASD children and
may be associated with their worsening behavioral
symptoms/cognitive skills with immune insults. Devel-
opment of SPAD in these ASD children may also be a
part of their clinical spectrum associated with these
immune abnormalities.
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